Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment

Eligibility criteria

Inclusion Criteria (treatment-naïve patients): • Diagnosed adult patients (at least 18 years of age) with prolactinoma-induced hyperprolactinemia, defined as a prolactin level ≥ two times the local laboratory maximum and radiographic criteria, based on current guidelines. Inclusion Criteria (treatment-naïve patients): • Diagnosed adult patients (at least 18 years of age) with prolactinoma-induced hyperprolactinaemia based on current guidelines. • Patients treated with cabergoline as DA therapy and prolactin levels within the normal range Exclusion Criteria: • alternative explanation for hyperprolactinaemia • Active substance use disorder within the last six months • Current or previous psychotic disorder • Pregnancy or breastfeeding within the last 8 weeks • Severe hepatic insufficiency or cholestasis • Child Pugh C or • AST/ ALT \> 3 x the upper limit of normal ULN or • Cholestasis (total bilirubin \> 2x ULN) • Severe renal impairment (eGFR \< 30 ml/min) • History of pulmonary, pericardial, and/or retroperitoneal fibrotic disorders • Concomitant treatment with strong or moderate CYP3A4 inhibitors • Local complications on morphological imaging, related to signs or clinical symptoms which make surgical intervention necessary or a clear patient's preference for surgical treatment • Gastrointestinal disease or previous surgery: chronic active inflammatory bowel disease, active gastrointestinal ulcer disease, or surgery on the gastrointestinal tract (e.g. sleeve stomach, gastric band) • Patient incapable of giving informed consent due to cognitive impairment or other reasons (e.g., legal incapacity)